| 摘要 |
The present invention relates to a system for the generation of antibody fusion proteins which has utility in the production of recombinant molecules that possess novel, clinically relevant biological activity. The antibody fusion proteins of the invention may be used therapeutically to deliver biologically active ligands to a desired tissue. In particular embodiments of the invention, the antibody fusion protein comprises a biologically active ligand which is a lymphokine, including, in a specific embodiment, interleukin-2. Because interleukin-2 induces lymphocyte proliferation, fused antibody that targets interleukin-2 (IL-2) to a malignant or infected tissue can produce localized amplification of the immune response toward the diseased tissue, and thereby facilitate the destruction of the infected or malignant tissue. In a specific embodiment of the invention, a fused antibody is produced which comprises a variable region of the anti-tumor antigen monoclonal antibody L6 and active IL-2. Additional embodiments of the invention relate to fused antibodies which comprise an immunoglobulin variable region and a biologically active ligand which is a-non- lymphokine cellular factor. In a specific embodiment of the invention, a fused antibody is produced which comprises a variable region of the anti-tumor antigen monoclonal antibody L6 and active platelet factor 4, a molecule associated with antagonism of angiogenesis, inhibition of suppressor T lymphocyte development, chemotaxis and heparin binding.
|
